Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
- Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
- 03/08/2022
|
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
- COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
- 02/28/2022
|
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
- Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 02/18/2022
|
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
- The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 02/02/2022
|
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
- Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.
- 02/01/2022
|
Cortexyme Stock Sinks After FDA Puts Application on Hold
- Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold.
- 01/26/2022
|
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
- The Company plans to provide additional updates pending continued engagement with FDA.
- 01/26/2022
|
Why Cortexyme Stock Imploded in 2021
- A key clinical setback sent investors to the exits last year.
- 01/12/2022
|
3 Most-Shorted Stocks at 52-Week Lows to Buy
- In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on InvestorPlace.
- 01/07/2022
|
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
- Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on InvestorPlace.
- 12/17/2021
|
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
- CRTX reported partially promising results on October 26, 2021, which have been perceived as a complete failure by the market.
- 12/15/2021
|
5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard
- Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
- 12/06/2021
|
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
- Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
- 12/01/2021
|
Cortexyme: A Challenging Path Forward
- Cortexyme: A Challenging Path Forward
- 11/17/2021
|
Why Are Cortexyme Shares Falling Today?
- Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference. The 643-participant 48-week GAIN Trial failed to meet statistical significance on its co-primary cognitive and functional endpoints in the overall cohort.
- 11/11/2021
|
Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?
- Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
- 11/05/2021
|
This Is What Whales Are Betting On Cortexyme
- Someone with a lot of money to spend (and possibly insider knowledge) has taken a bullish stance on Cortexyme (NASDAQ:CRTX). And retail traders should know.
- 11/03/2021
|
Down 76%: Is Cortexyme Stock a Bargain?
- The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
- 10/28/2021
|
Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
- Another new drug candidate for the treatment of Alzheimer's disease failed miserably in a clinical trial.
- 10/28/2021
|
CRTX Stock: What to Know as Cortexyme Plummets 75%
- Today, investors in CRTX stock lament a rather poor announcement from the company that a key clinical trial missed its primary endpoint. The post CRTX Stock: What to Know as Cortexyme Plummets 75% appeared first on InvestorPlace.
- 10/27/2021
|
Why Cortexyme Shares Are Falling
- Cortexyme Inc (NASDAQ: CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the additional top-line results from the GAIN Trial at the upcoming 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference on Thursday, November 11 at 11:35 a.m.
- 10/27/2021
|
Here's Why Cortexyme Is Imploding on Wednesday
- An Alzheimer's disease trial failure was much worse than the company's relatively upbeat look forward suggests.
- 10/27/2021
|
Cortexyme's stock tumbles on failed clinical trial for Alzheimer's drug
- Shares of Cortexyme Inc. CRTX, -73.76% tumbled 72.7% in trading on Wednesday, the day after the company said a late-stage clinical trial evaluating its experimental Alzheimer's disease treatment failed to meet the study's endpoints. Cortexyme's stock is down 43.3% this year; the S&P 500 SPX, -0.09% is up 21.8%.
- 10/27/2021
|
Why Cortexyme Shares Are Plunging 70% After Hours
- Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX) reported Phase 2/3 GAIN trial data for its Alzheimer's disease trial Tuesday.
- 10/26/2021
|
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
- Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed.
- 10/16/2021
|
Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
- Cortexyme has a unique hypothesis- that Alzheimer's disease (AD) is caused by a neurological infection with P. gingivalis. There is a surprising amount of data generated by the company and independent labs supporting this hypothesis.
- 10/11/2021
|
Cortexyme: Alzheimer's Readout In November A Binary Event
- CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD). Top line results for AD Phase 2/3 trial expected mid-November; success would be one of the greatest medical breakthroughs in modern history.
- 09/12/2021
|
Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case
- Screen capture via Cortexyme animation. A Bigger Bubble Than The Late '90s
- 08/16/2021
|
CRTX Stock Price Increased 47.32%: Why It Happened
- The stock price of Cortexyme Inc (NASDAQ: CRTX) increased 47.32%. This is why it happened.
- 08/09/2021
|
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. “There continues to be a large unmet need for coronavirus treatment. The targ
- 07/23/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
- 03/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
- 03/12/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
- 03/03/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 02/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
- NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
- 02/18/2021
|
Cortexyme: The OLE Study Hold Does Not Matter
- Cortexyme: The OLE Study Hold Does Not Matter
- 02/17/2021
|
Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease
- Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension (OLE) phase of Phase 2/3 GAIN trial of Cortexyme Inc (NASDAQ: CRTX) evaluating atuzaginstat (COR388) in patients with mild to moderate Alzheimer's disease. The adverse events were reversible and without any known long-term adverse effects for the participants.
- 02/16/2021
|
Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer's Disease
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, received a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension (OLE) phase of the company's ongoing Phase 2/3 study, the GAIN Trial. Under the hold, no new participants will be enrolled in the OLE and curr
- 02/15/2021
|
Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therapeutics for degenerative diseases, today announced a series of leadership appointments to support the continued advancement and commercial planning of atuzaginstat, as well as the company's pipeline expansion and regulatory affairs capabilities. “Expanding Cortexyme's leadership team strengthens our
- 02/10/2021
|
Cortexyme: A Fresh Perspective In Alzheimer's
- CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.
- 01/12/2021
|
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
- Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
- 01/06/2021
|
Cortexyme's Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer's Disease Successfully Advances Past Interim Analysis
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases, today announced that the independent Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and recommended Cortexyme continue the Phase 2/3 GAIN Trial of atuzaginstat (COR388) as planned to the 1-year endpoint. The interim analysis included approximately 300 patients who hav
- 12/04/2020
|
4,400 Shares in Cortexyme, Inc. (NASDAQ:CRTX) Acquired by TD Asset Management Inc.
- TD Asset Management Inc. acquired a new stake in Cortexyme, Inc. (NASDAQ:CRTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,400 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. Several other large investors also recently made changes […]
- 09/17/2020
|
Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the second quarter 2020 and provided an update on its business.
- 08/17/2020
|
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
- Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation. Calliditas Therapeutics inks deal for Genkyotex Acquisition.
- 08/16/2020
|
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients
- Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease (AD) has reached 500 patients toward the study’s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial’s protocol includes an interim analysis on the study’s co-primary cognitive and functional endpoints after approximately 300 patients reach 24 weeks of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results of the GAIN Trial’s final analysis, to be performed once all study subjects complete the one-year study, are expected in Q4 2021.
- 08/14/2020
|
We're Hopeful That Cortexyme (NASDAQ:CRTX) Will Use Its Cash Wisely
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 08/12/2020
|
Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 08/12/2020
|
Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the following two investor conferences in August 2020:
- 08/06/2020
|
Bristol Myers Squibb NDA, And Other News: The Good, Bad And Ugly Of Biopharma
- Bristol Myers Squibb resubmits multiple myeloma therapy application. Onconova reports progress of INSPIRE trial data analysis.
- 07/30/2020
|
Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s chief scientific officer and co-founder, will participate in a fireside chat hosted by LifeSci Capital on Thursday, July 30 at 3:00 p.m. EDT / 12:00 p.m. PDT. The conversation will focus on the link between P. gingivalis and Alzheimer’s disease pathology.
- 07/29/2020
|
Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases
- Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced new preclinical data demonstrating the role of the bacterium P. gingivalis in Alzheimer’s disease (AD) and cardiovascular disease, providing a potential explanation for why the two diseases often occur together. Cortexyme also provided data demonstrating the therapeutic potential of its lead compound, atuzaginstat (COR388), in treating both diseases. This data, along with two other poster presentations on atuzaginstat, are being presented by Cortexyme at the Alzheimer's Association International Conference® 2020 (AAIC®), which is taking place virtually from July 27-31.
- 07/28/2020
|
Stocks To Watch: Big Focus On Big Tech
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 07/25/2020
|
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
- Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer’s Association International Conference® 2020 (AAIC®). The largest international meeting dedicated to advancing dementia science, AAIC will be held as a virtual event this year from July 27-31, 2020.
- 07/22/2020
|
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
- Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed wit
- 07/22/2020
|
Legal & General Group Plc Trims Position in Cortexyme, Inc. (NASDAQ:CRTX)
- Legal & General Group Plc lessened its stake in Cortexyme, Inc. (NASDAQ:CRTX) by 22.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,809 shares of the biopharmaceutical company’s stock after selling 517 shares during the period. Legal & General Group Plc’s holdings in […]
- 07/06/2020
|
V&M Premium Portfolio: 2020 Mid-Year Report Card Through Week 26
- The Premium Portfolio is up +14.43% YTD, while the benchmark S&P 500 Index is down -6.86% through June 26th. The Premium Portfolio has beaten the S&P 500 every
- 06/29/2020
|
HC Wainwright Initiates Coverage on Cortexyme (NASDAQ:CRTX)
- Analysts at HC Wainwright initiated coverage on shares of Cortexyme (NASDAQ:CRTX) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $76.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 50.50% from the stock’s current price. […]
- 06/26/2020
|
Cortexyme (NASDAQ:CRTX) Stock Rating Lowered by Zacks Investment Research
- Cortexyme (NASDAQ:CRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The company’s […]
- 06/26/2020
|
Citigroup Inc. Has $158,000 Stock Holdings in Cortexyme, Inc. (NASDAQ:CRTX)
- Citigroup Inc. increased its position in Cortexyme, Inc. (NASDAQ:CRTX) by 50.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,470 shares of the biopharmaceutical company’s stock after purchasing an additional 1,157 shares during the quarter. Citigroup Inc.’s holdings in […]
- 06/18/2020
|
Insider Weekends: Director Of Accelerate Diagnostics Adds To His Stock
- Insider buying decreased significantly last week. Notable Insider Buys: Accelerate Diagnostics, Inc., Keurig Dr Pepper Inc., Vishay Precision Group, Inc., Corte
- 06/15/2020
|
4 Biotech Stocks That Are Seeing Big Buys in June
- Allogene Therapeutics, Personalis, Cortexyme, and La Jolla Pharmaceutical have all seen large stock purchases by insiders and big investors this month.
- 06/14/2020
|
Hedge Funds Are Buying Cortexyme, Inc. (CRTX)
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 06/12/2020
|
Cortexyme: A New Approach To Defeat Alzheimer's Disease (NASDAQ:CRTX)
- Alzheimer's disease remains an unbreakable wall for biotech companies for decades. The recent fails in beta-amyloid thesis create an opportunity for better unde
- 06/12/2020
|
David Lamond Acquires 49,125 Shares of Cortexyme, Inc. (NASDAQ:CRTX) Stock
- Cortexyme, Inc. (NASDAQ:CRTX) Director David Lamond acquired 49,125 shares of Cortexyme stock in a transaction that occurred on Thursday, June 4th. The stock was acquired at an average cost of $41.73 per share, for a total transaction of $2,049,986.25. Following the purchase, the director now owns 301,829 shares of the company’s stock, valued at $12,595,324.17. […]
- 06/10/2020
|
Cortexyme Announces "Atuzaginstat" Selected as First-in-Class Nonproprietary Name for COR388
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced that the International Nonproprietary Naming Committee of the World Health Organization (WHO) has selected atuzaginstat (pronounced "a too za’ gin stat") as the proposed International Nonproprietary Name, or pINN, for the company’s lead product candidate COR388. Atuzaginstat is an oral, twice-daily investigational medicine in late stage clinical development for Alzheimer’s disease that is designed to inhibit lysine gingipain, a virulence factor protease released by P. gingivalis.
- 06/09/2020
|
Benzinga's Top Upgrades, Downgrades For June 2, 2020
- Upgrades * For Eaton Vance Corp (NYSE: EV), B of A Securities upgraded the stock from Neutral to Buy. In the second quarter, Eaton Vance showed an EPS of $0.80, compared to $0.89 from the year-ago quarter. The stock has a 52-week-high of $51.79 and a 52-week-low of $23.59. Eaton Vance's stock last closed at $37.21 per share. * For W.W. Grainger Inc (NYSE: GWW), Longbow Research upgraded the stock from Neutral to Buy. W.W. Grainger earned $4.24 in the first quarter, compared to $4.51 in the year-ago quarter. The stock has a 52-week-high of $346.60 and a 52-week-low of $200.61. W.W. Grainger's stock last closed at $306.14 per share. * Citigroup upgraded the stock for Hess Corp (NYSE: HES) from Neutral to Buy. In the first quarter, Hess showed an EPS of ($0.60), compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $74.11 and a 52-week-low of $26.06. Hess's stock last closed at $48.70 per share. * Gordon Haskett upgraded the stock for Lowe's Companies Inc (NYSE: LOW) from Hold to Buy. In the first quarter, Lowe's Companies showed an EPS of $1.77, compared to $1.22 from the year-ago quarter. The stock has a 52-week-high of $131.40 and a 52-week-low of $60.00. Lowe's Companies's stock last closed at $129.35 per share. * For RH (NYSE: RH), Gordon Haskett upgraded the stock from Reduce to Hold. For the fourth quarter, RH had an EPS of $3.72, compared to year-ago quarter EPS of $3.00. The stock has a 52-week-high of $256.27 and a 52-week-low of $73.14. RH's stock last closed at $212.51 per share. Downgrades * Baird changed the rating for Cognex Corp (NASDAQ: CGNX) from Neutral to Underperform. Cognex earned $0.11 in the first quarter, compared to $0.17 in the year-ago quarter. The stock has a 52-week-high of $64.28 and a 52-week-low of $35.20. Cognex's stock last closed at $56.86 per share. * Goldman Sachs downgraded the stock for Tractor Supply Co (NASDAQ: TSCO) from Buy to Neutral. For the first quarter, Tractor Supply had an EPS of $0.71, compared to year-ago quarter EPS of $0.63. The stock has a 52-week-high of $124.43 and a 52-week-low of $63.89. Tractor Supply's stock last closed at $122.66 per share. * Cantor Fitzgerald downgraded the stock for Evolent Health Inc (NYSE: EVH) from Overweight to Neutral. In the first quarter, Evolent Health showed an EPS of ($0.14), compared to ($0.31) from the year-ago quarter. The stock has a 52-week-high of $12.01 and a 52-week-low of $3.50. Evolent Health's stock last closed at $6.83 per share. * DA Davidson downgraded the stock for 1-800-Flowers.com Inc (NASDAQ: FLWS) from Neutral to Underperform. In the third quarter, 1-800-Flowers.com showed an EPS of ($0.14), compared to ($0.13) from the year-ago quarter. The stock has a 52-week-high of $25.50 and a 52-week-low of $11.15. 1-800-Flowers.com's stock last closed at $22.84 per share. * For Triumph Bancorp Inc (NASDAQ: TBK), Wells Fargo downgraded the stock from Equal-Weight to Underweight. Triumph Bancorp earned ($0.18) in the first quarter, compared to $0.55 in the year-ago quarter. The stock has a 52-week-high of $43.15 and a 52-week-low of $19.03. Triumph Bancorp's stock last closed at $24.37 per share. * Stifel changed the rating for Tellurian Inc (NASDAQ: TELL) from Hold to Sell. Tellurian earned ($0.18) in the first quarter, compared to ($0.16) in the year-ago quarter. The stock has a 52-week-high of $9.28 and a 52-week-low of $0.67. Tellurian's stock last closed at $1.06 per share. * For Lululemon Athletica Inc (NASDAQ: LULU), Wells Fargo downgraded the stock from Overweight to Equal-Weight. For the fourth quarter, Lululemon Athletica had an EPS of $2.28, compared to year-ago quarter EPS of $1.85. The stock has a 52-week-high of $310.22 and a 52-week-low of $128.84. Lululemon Athletica's stock last closed at $308.69 per share. * For Iterum Therapeutics PLC (NASDAQ: ITRM), RBC Capital downgraded the stock from Outperform to Sector Perform. In the first quarter, Iterum Therapeutics showed an EPS of ($0.90), compared to ($1.44) from the year-ago quarter. The stock has a 52-week-high of $7.65 and a 52-week-low of $1.40. Iterum Therapeutics's stock last closed at $1.70 per share. Initiations * Jefferies initiated coverage on Cortexyme Inc (NASDAQ: CRTX) with a Buy rating. The price target for Cortexyme is set at $59.00. In the first quarter, Cortexyme showed an EPS of ($0.61), compared to ($1.61) from the year-ago quarter. The stock has a 52-week-high of $73.84 and a 52-week-low of $19.35. Cortexyme's stock last closed at $44.44 per share. * With a rating of Buy, Ladenburg Thalmann initiated coverage on MTBC Inc (NASDAQ: MTBC). The price target is set at $10.75 for MTBC. For the first quarter, MTBC had an EPS of $0.03, compared to year-ago quarter EPS of $0.11. The stock has a 52-week-high of $7.75 and a 52-week-low of $3.25. MTBC's stock last closed at $6.71 per share. * Guggenheim initiated coverage on Progyny Inc (NASDAQ: PGNY) with a Buy rating. The price target for Progyny is set at $30.00. Interestingly, in the first quarter, Progyny's EPS was $0.04. The stock has a 52-week-high of $36.50 and a 52-week-low of $13.29. Progyny's stock last closed at $24.00 per share. * Cowen & Co. initiated coverage on Slack Technologies Inc (NYSE: WORK) with an Outperform rating. The price target for Slack Technologies is set at $45.00. Slack Technologies earned ($0.04) in the fourth quarter. The stock has a 52-week-high of $42.00 and a 52-week-low of $15.10. Slack Technologies's stock last closed at $37.18 per share. * Baird initiated coverage on Pros Holdings Inc (NYSE: PRO) with an Outperform rating. The price target for Pros Holdings is set at $45.00. In the first quarter, Pros Holdings showed an EPS of ($0.23), compared to ($0.11) from the year-ago quarter. The stock has a 52-week-high of $75.39 and a 52-week-low of $19.73. Pros Holdings's stock last closed at $39.90 per share. * Baird initiated coverage on Sprout Social Inc (NASDAQ: SPT) with an Outperform rating. The price target for Sprout Social is set at $33.00. Sprout Social earned ($0.14) in the first quarter. The stock has a 52-week-high of $29.83 and a 52-week-low of $10.54. Sprout Social's stock last closed at $29.09 per share.See more from Benzinga * Recap: Cracker Barrel Q3 Earnings * 15 Consumer Cyclical Stocks Moving In Tuesday's Pre-Market Session * Dick's Sporting Goods: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/02/2020
|
Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 2:30 p.m. EDT / 11:30 a.m. PDT.
- 05/27/2020
|
Insider Weekends: Moderna Executives Go On A Selling Spree
- Insider buying decreased significantly last week. Notable Insider Buys: Mercury General Corporation, Cortexyme, Inc., New Mountain Finance Corporation, Berkshir
- 05/25/2020
|
Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock?
- It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- 05/14/2020
|
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the first quarter 2020 and provided an update on its business.
- 05/12/2020
|
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative di
- 05/12/2020
|
Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on Wednesday, May 13, 2020 at 1:00 p.m. EDT / 10:00 a.m. PDT.
- 05/07/2020
|
Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it
- 05/07/2020
|
Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the publication of research further documenting the ability of the pathogen Porphyromonas gingivalis to invade neurons and trigger Alzheimer’s-like neuropathology. The findings are to be published in the June 2020 issue of the Journal of Alzheimer’s Disease [JAD 75(4)]; an early online version of the paper is available now so that the important findings can be rapidly disseminated to the research community.
- 05/06/2020
|
Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary
- Cortexyme, Inc. (Nasdaq: CRTX), a biopharmaceutical company developing treatments for Alzheimer’s disease (AD) and other degenerative diseases, today announced Caryn McDowell, J.D. will join the company’s executive leadership team as Chief Legal and Administrative Officer and Corporate Secretary, effective May 11, 2020. In this newly created role, Ms. McDowell will lead Cortexyme’s legal, corporate governance, compliance, human resources, and administrative functions.
- 04/30/2020
|
Summit Financial Group Reports First Quarter 2020 Results
- MOOREFIELD, W.V., April 30, 2020 -- Summit Financial Group, Inc. (“Company” or “Summit”) (NASDAQ: SMMF) today reported first quarter 2020 net income of $4.51 million, or $0.35.
- 04/30/2020
|
Further Metallurgical Test Work Continues to Add Improvements and Modeled Revenue Increases at Alpala
- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (CGP.V) (GWN.F) (GWN.BE) (CTNXF) is pleased to announce the following update on the exploration program at its Cascabel copper-gold porphyry joint venture project in northern Ecuador, in which the Company has a 15% interest1 financed
- 04/29/2020
|
During Ramadan, our ritual of gathering won’t happen but our values of community remain
- This year, we plan on holding our prayers at home as a family and focusing on the blessings of health and wellness despite social distancing.
- 04/24/2020
|
Cortexyme, Inc. (NASDAQ:CRTX) Position Increased by Bank of New York Mellon Corp
- Bank of New York Mellon Corp boosted its holdings in Cortexyme, Inc. (NASDAQ:CRTX) by 180.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,867 shares of the biopharmaceutical company’s stock after acquiring an additional 25,014 shares during the period. Bank of New […]
- 04/21/2020
|
Cornerstone Reports Significant Increase in Online Learning as Organizations Transition to Remote Work Globally
- New data from the Cornerstone Institute for People Development reveals 27.5 million hours were spent on Cornerstone Learning in March 2020.
- 04/17/2020
|
Cortexyme, Inc. (NASDAQ:CRTX) Short Interest Up 16.9% in March
- Cortexyme, Inc. (NASDAQ:CRTX) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,630,000 shares, a growth of 16.9% from the March 15th total of 1,393,800 shares. Currently, 13.8% of the shares of the company are sold short. Based on an average daily trading […]
- 04/17/2020
|
Bramaderos Au Cu Project, Ecuador – High-grade surface samples at Espiritu epithermal gold-silver target
- OTTAWA, April 08, 2020 -- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV-CGP) (F-GWN) (B-GWN) (OTC-CTNXF) is pleased to provide an update on its.
- 04/08/2020
|
Alpala Mineral Resource Estimate # 3 delivers significant tonnage conversion to Measured Category
- OTTOWA, April 07, 2020 -- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV:CGP) (Frankfurt:GWN) (Berlin:GWN) (OTC:CTNXF) is pleased to announce the.
- 04/07/2020
|
Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the virtual LifeSci Capital Alpha Series Conference on Thursday, April 9, 2020 at 1:00 p.m. EDT / 10:00 a.m. PDT.
- 04/06/2020
|
Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced new data supporting the ability of the pathogen Porphyromonas gingivalis to invade brain cells and trigger characteristic Alzheimer’s pathology including synaptic loss, ultrastructural changes, and inflammation. The data is being presented this week as part of the Advances in Alzheimer’s and Parkinson’s Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5.
- 04/02/2020
|
Bramaderos Au Cu Project, Ecuador – Exploration breakthrough leads to identification of numerous higher grade gold-copper porphyry targets
- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV-CGP) (F-GWN) (B-GWN) (OTC-CTNXF) is pleased to provide an update on its Bramaderos gold and copper project in southern Ecuador, which it is exploring together with ASX listed Sunstone Metals Inc. under joint venture agreement (
- 03/26/2020
|
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Cortexyme (CRTX)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elanco Animal Health (ELAN) and Cortexyme (CRTX). Elanco Animal Health
- 03/25/2020
|
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and Cortexyme (NASDAQ: CRTX)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elanco Animal Health (
ELAN
–
Research Report
) and Cortexyme (
CRTX
–
Research Report
).
Elanco Animal Health (ELAN)
Credit Suisse analyst
Erin Wright
maintained a
Buy
- 03/25/2020
|
Temporary suspension of activities at Cascabel and other Cornerstone Projects due to Coronavirus Precautions
- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV-CGP) (F-GWN) (B-GWN) (OTC-CTNXF) announces that exploration activities at the Cascabel Project and other Cornerstone Projects in Ecuador have been suspended in line with the directives of the Ecuadorian government decree declaring
- 03/25/2020
|
Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced financial results for the fourth quarter and full year 2019 and provided an update on its business.
- 03/17/2020
|
Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients
- Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease has reached 300 patients toward the study’s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of COR388, Cortexyme’s lead investigational medicine, in patients with mild to moderate Alzheimer’s disease. GAIN’s protocol includes an interim analysis for overwhelming efficacy on its co-primary cognitive and functional endpoints after 300 patients reach six months of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results from the GAIN Trial’s final analysis, to be performed once all study subjects complete one year of treatment, are expected in Q4 2021.
- 03/16/2020
|
Cascabel (Alpala Deposit) Update
- OTTAWA, Ontario, March 11, 2020 -- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV-CGP) (F-GWN) (B-GWN) (OTC-CTNXF) is pleased to provide the.
- 03/11/2020
|
Cornerstone Christian has simple goal in Div. IV state girls basketbal semi: ‘Play our game’
- No. 1-ranked Fort Loramie offers an imposing challenge in Thursday's 6 p.m. semifinal in Columbus.
- 03/11/2020
|
Cornerstone (CNR) Acquires Kleary, Fortifies Siding Business
- Cornerstone Building Brands (CNR) strengthens its position in the fastest-growing segment of the residential cladding market with Kleary buyout.
- 03/05/2020
|
Surprising Norton proves ‘anything can happen’; Who wins Division I at Canton? OHSAA girls basketball regional preview
- By the end of the week, we'll know which Northeast Ohio girls basketball teams will be headed to Columbus for the OHSAA state semifinals in each division.
- 03/02/2020
|
Pennant Announces Agreement to Form Home Health Joint Venture
- The Pennant Group, Inc. (PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that a subsidiary of Cornerstone Healthcare, Inc., its home health and hospice portfolio company, has entered into an agreement to form a home health
- 02/27/2020
|
Cornerstone OnDemand Announces Fourth Quarter and Fiscal Year 2019 Financial Results
- People development solution provider Cornerstone OnDemand, Inc. (NASDAQ: CSOD) today announced results1 for its fourth quarter ended December 31, 2019. The Company has provided supplemental financial information located on its Investor Relations website at http://investors.cornerstoneondemand.com.
- 02/24/2020
|
Cornerstone to Acquire Saba
- Cornerstone OnDemand, Inc. (NASDAQ:CSOD), a global leader in people development solutions, today announced it has entered into a definitive agreement to acquire Saba, a global leader in talent experience solutions and a portfolio company of Vector Capital. Saba has over 20 years of industry experience
- 02/24/2020
|
Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 01/05/2020
|
Last year's Bay Area IPO performances show why it pays to be an insider
- Timing is everything: Here's a look at the big gap in returns for public and private investors in the best performing new Bay Area stocks from last year.
- 01/03/2020
|
Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX)
- We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- 12/22/2019
|
The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber
- The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber
- 12/13/2019
|
Gum infection could be linked to Alzheimer’s, study says
- A gum infection was found to be a potential risk factor of Alzheimer’s disease in a study published Wednesday in the journal Science Advances. The bacteria Porphyromonas gingivalis, known as …
- 01/28/2019
|
6 Startups Searching for a Cure for Alzheimer's
- Memory loss. Fatigue. Confusion. Behavior change. Alzheimer’s disease, or simply Alzheimer’s, is an incurable, crippling condition that starts with these tell-tale symptoms and ends in death three to eight years after diagnosis when your brain has turned into cauliflower. The disease is the most common form of dementia, making up 60 percent to 70 percent of all cases. If you’re keeping up with your Netflix binge list, you’ll remember it was featured in the 2014 film Still Alice where we watched Julianne Moore forget her to-do list for almost two hours. About 50 million people worldwide suffer from this condition,
- 09/10/2018
|
